154 related articles for article (PubMed ID: 21757598)
1. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas.
Tsuta K; Liu DC; Kalhor N; Wistuba II; Moran CA
Am J Clin Pathol; 2011 Aug; 136(2):252-9. PubMed ID: 21757598
[TBL] [Abstract][Full Text] [Related]
2. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
3. Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency.
Laflamme P; Mansoori BK; Sazanova O; Orain M; Couture C; Simard S; Trahan S; Manem V; Joubert P
Hum Pathol; 2020 Dec; 106():74-81. PubMed ID: 33007357
[TBL] [Abstract][Full Text] [Related]
4. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray.
Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF
Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351
[TBL] [Abstract][Full Text] [Related]
5. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
Puripat N; Loharamtaweethong K
Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
[TBL] [Abstract][Full Text] [Related]
6. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
7. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
Medani H; Elshiekh M; Naresh KN
J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
[TBL] [Abstract][Full Text] [Related]
8. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT
J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230
[TBL] [Abstract][Full Text] [Related]
9. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.
Kim YJ; Ketter R; Steudel WI; Feiden W
Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279
[TBL] [Abstract][Full Text] [Related]
11. SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.
Yu L; Dong Y; Xue J; Xu S; Wang G; Kuang D; Duan Y
Diagn Pathol; 2022 Jan; 17(1):2. PubMed ID: 34996493
[TBL] [Abstract][Full Text] [Related]
12. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
13. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.
Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP
Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989
[TBL] [Abstract][Full Text] [Related]
14. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
[TBL] [Abstract][Full Text] [Related]
15. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
Metro G; Ricciuti B; Chiari R; Baretti M; Falcinelli L; Giannarelli D; Sidoni A; Mountzios G; Crinò L; Bellezza G; Rebonato A; Ferolla P; Toschi L
Lung Cancer; 2016 May; 95():82-7. PubMed ID: 27040856
[TBL] [Abstract][Full Text] [Related]
17. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
18. PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens.
Sica G; Vazquez MF; Altorki N; Port J; Lee PC; Liu Y; Hyjek E; Saqi A
Am J Clin Pathol; 2008 Apr; 129(4):556-62. PubMed ID: 18343782
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
20. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.
Ribalta T; McCutcheon IE; Aldape KD; Bruner JM; Fuller GN
Am J Surg Pathol; 2004 Nov; 28(11):1532-6. PubMed ID: 15489659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
